Samuel Yoon

Aug 21, 2024 | jamanetwork.com | Joshua D. Wallach |Joseph S. Ross |Samuel Yoon |Harry Doernberg

Surrogate Markers and Clinical Outcomes—Reply Surrogate Markers and Clinical Outcomes for Nononcologic Chronic Disease Treatments Joshua D. Wallach, PhD, MS; Samuel Yoon, BS, BA; Harry Doernberg, MM; Laura R. Glick, MD; Oriana Ciani, PhD; Rod S. Taylor, PhD; Maryam Mooghali, MD; Reshma Ramachandran, MD, MHS, MPP; Joseph S.

Apr 22, 2024 | jamanetwork.com | Joshua D. Wallach |Samuel Yoon |Harry Doernberg |Laura R Glick

Associations Between Surrogate Markers and Clinical Outcomes for Nononcologic Chronic Disease Treatments Key PointsQuestion  What is the strength of association between surrogate markers used as primary end points in clinical trials to support Food and Drug Administration (FDA) approval of drugs treating nononcologic chronic diseases and clinical outcomes?